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Summary 
Positron emission tomography (PET) was used to quant i fy 
the e f fec t  of caf fe ine on whole brain and regional cerebral 
blood flow (CBF) in humans. A mean dose of 250 mg of caffeine 
produced approximately a 30% decrease in whole brain CBF; 
regional di f ferences in caffeine e f fec t  were not observed. 
Pre-caffeine CBF strongly influenced the magnitude of the 
caffeine-induced decrease. Caffeine decreased PaCO 2 and 
increased systo l ic  blood pressure s ign i f i can t l y ;  the change 
in PaCO 2 did not account for  the change in CBF. Smaller 
increases in d ias to l i c  blood pressure, heart rate, plasma 
epinephrine and norepinephrine, and subject ive ly  reported 
anxiety were also observed. 
Caffeine is a widely-consumed methylxanthine stimulant (1); average 
dai ly  intake in the USA is 200-300 mg/day (2). I t  is completely absorbed 
a f te r  oral administrat ion and has a plasma h a l f - l i f e  of 3-10 hours (3). 
Phys io log ica l ly ,ca f fe ine decreases cerebral blood flow (CBF) (4-6), raises 
plasma epinephrine levels (7,8),  and functions as an antagonist at the adeno- 
sine receptor (9-12). Caffeine attenuates anoxia-induced (13) and 
hypercapnia-induced (14) increases in CBF, but does not inf luence the auto- 
regulatory e f fects  on CBF which occur in response to hypotension (15). 
Caffeine might also in terac t  with the benzodiazepine macromolecular receptor 
complex through i ts  adenosinergic e f fec t  (16). Caffeine can produce anxiety- 
l i ke  symptoms (17,18), especia l ly  in people with panic disorder (19-21). I t  
is controversial  whether anxiety produces speci f ic  changes in CBF; some 
studies have reported ef fects  (22-25), but another has not (26). 
The present study involved quant i f icat ion and anatomical loca l iza t ion 
of the ef fects  of epidemiological ly relevant doses of caffeine on CBF by 
positron emission tomography (PET). Based on the observations that caffeine 
can be anxiogenic and that anxiety might a f fec t  CBF, we also intended to 
test  the hypothesis that patients with panic disorder might have a d i f f e ren t  
magnitude or anatomical pattern of CBF response to caffeine than normal 
subjects. However, because the e f fec t  of caffeine on CBF was so robust and 
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the d i f fe rence between pat ients and normal subjects was so smal l ,  we 
emphasize the resu l ts  of in t ravenously  administered caf fe ine on CBF as the 
sample of e ight  subjects ra ther  than four pat ients  and four normal cont ro ls ;  
d i f ferences between pat ients and normal subjects are reported where they 
were observed. Because resu l t s  with intravenous caf fe ine might not be com- 
parable to the same dose given o r a l l y ,  two addi t iona l  normal subjects received 
oral ca f fe ine .  
Methods 
Eight subjects (two females and two males wi th panic disorder and four 
male normal subjects, mean age = 26.3 years) received intravenous ca f fe ine ;  
two addi t iona l  normal subjects (both male and both 24 years old) received 
oral ca f fe ine .  A l l  I0 subjects reported average coffee intake (the major 
source of ca f fe ine  in most d ie ts )  of two or fewer cups per day, and a l l  
subjects were ins t ruc ted to r e f r a i n  from coffee consumption for  12 hours 
before the study. Al l  were medical ly  healthy and medicat ion- f ree.  The study 
was approved by the Un ive rs i t y  of Michigan Medical Center I n s t i t u t i o n a l  
Review Board for  Use of Human Subjects in Research; a l l  subjects gave wr i t t en  
informed consent. 
Each of the e ight  subjects who received intravenous caf fe ine (ca f fe ine  
a l ka lo id  in so lu t ion as ca f fe ine  sodium benzoate: Pasadena Research 
Laborator ies,  Inc . ,  Pasadena, CA 91107) received the fo l lowing four scans in 
one experimental session of 3-4 hours durat ion:  (a) basel ine,  (b) a f t e r  a 
sa l ine  placebo in fus ion ,  and (c & d) 15 and 45 minutes a f t e r  intravenous 
caf fe ine admin is t ra t ion .  Because pat ients  with panic d isorder might vary in 
t h e i r  ind iv idua l  tolerances fo r  the anxiogenic e f fec ts  of ca f fe ine ,  each 
pa t ien t  was tested on a day p r i o r  to the PET study for  a b i l i t y  to l i e  q u i e t l y  
a f t e r  intravenous caf fe ine admin is t ra t ion  at graded, ascending doses; f i na l  
to le ra ted  doses for  the four pat ients  ranged from 120-350 mg, wi th a mean 
of 250 mg. Doses were 250 mg each fo r  the four normal subjects. 
Subjects remained supine throughout the study; during the scans eyes 
were closed and room noise was minimized. During each scan a r t e r i a l  blood 
was sampled two minutes a f t e r  i n j ec t i on  of pos i t ron - l abe l l ed  water 
([150]-H20) for  blood gases, and plasma epinephrine, norepinephrine, and 
caf fe ine concentrat ions. Blood pressure, heart ra te ,  and ra t ings of 
subject ive anxiety  from zero ("none") to I00 ("most ever")  were determined at 
the end of each scan. Plasma caf fe ine was measured with HPLC; epinephrine 
and norepinephrine were measured by HPLC with electrochemical detect ion.  
Correct ion for  changes in PaC02 was made using the fo l lowing equation (26): 
CBF corrected to PaCO 2 of 40 t o r r  = CBF observed + 1.8 x (40 - PaC02). 
The l a s t  two normal subjects were scanned a f t e r  receiv ing 250 mg of 
o r a l l y  administered ca f fe ine .  Al l  of the same dependent var iab les  were 
determined except catecholamines. Scans performed were: (a) basel ine,  and 
(b-d) at 15, 45, and 75 minutes a f te r  caf fe ine admin is t ra t ion ;  no placebo 
scan was performed. For a l l  I0 subjects, there was a 14-minute minimum 
between a l l  scans. 
Scans were performed on a TCC PC-4600 tomograph with FWHM reso lu t ions of 
approximately 10 mm axia l  and I I  mm in-p lane.  Data acqu is i t i on  was cont in-  
uous from 40 seconds to 6 minutes a f t e r  in fus ion of 30 mCi of [150]-H20. CBF 
and p a r t i t i o n  coe f f i c i en t s  were estimated wi th a weighted in tegra l  technique 
invo lv ing  a single-compartment blood f low model and use of rad ia l  a r te ry  
blood to est imate the r a d i o a c t i v i t y  input funct ion to bra in.  Three rows 
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of detectors plus two c ross -s l i ces  produced f i v e  transverse scan s l i ces  from 
approximately 2.5 to 6.9 cm above the cantho-meatal l i ne .  
Regions of i n t e r e s t  (ROls) included whole brain ( to ta l  area fo r  a l l  f i v e  
s l i c e s ) ,  cerebral cortex (average f low in area of 25 mm-deep computer- 
generated co r t i ca l  peel fo r  a l l  f i v e  s l i ces )  and 12 ROls which were loca l i zed  
wi th an anatomic a t las  (27) and scaled to the dimensions of the PET images; 
these ROls were r i g h t  and l e f t  f ron ta l  lobes, temporal lobes, occ ip i t a l  
lobes, caudate nuc le i ,  thalamus, and cerebe l le r  hemispheres. D iv is ion  of the 
computer-generated ROls of the cerebral cortex in to  four quadrants permit ted 
r i g h t / l e f t  and a n t e r i o r / p o s t e r i o r  comparisons. 
PET image data were analyzed with and wi thout  cor rect ion for  PaC02, and 
wi th and wi thout  normal izat ion to whole brain CBF. Because normalizatXon 
did not a f f ec t  resu l t s ,  only non-normalized data are reported. S t a t i s t i c a l  
analyses were performed with between-within repeated-measures analyses of 
variance (ANOVAs--patients versus normals across four scan t imes),  paired and 
unpaired t - t e s t s ,  Pearson product-moment co r re la t i ons ,  and simple l i nea r  
regression. S ign i f icance leve ls  are defined as p < 0.05 fo r  two- ta i led  
tes ts ;  trends are defined as 0.05< p < 0 . I0 .  Percentages of varianc~ accounted 
fo r  by the s i g n i f i c a n t  F - ra t ios  in the ANOVAs were estimated as eta ~. 
Results 
In response to in t ravenously  administered ca f fe ine ,  whole brain CBF 
showed decreases of 31% at both 15 and 45 minutes a f t e r  in fus ion wi thout  
PaCO 2 cor rec t ion  (repeated-measures F = 18.1, df = 3,18, p < 0.0001; eta 2 = 
0.757 (Table 1), and 24% and 27%, respect ivel%, with correct ion (repeated- 
measures F = 11.6, df = 3,18, p < 0.0003; etaL = 0.66). The pre- t reatment 
mean whole-brain CBF level  was 46.6 ml/min/ lO0 gm of t i ssue.  Based on 
PaCO?-corrected data, there were pos i t i ve  but non -s ign i f i can t  cor re la t ions  
between the plasma caf fe ine  leve ls  and the magnitudes of decrease in CBF from 
pre-ca f fe ine  to 15 minutes post -ca f fe ine ( r  = +0.42), and from pre-ca f fe ine  
to 45 minutes pos t -ca f fe ine  ( r  = +0.35). A l i nea r  regression analys is of 
the change in whole brain CBF (ml/min/lO0 gm of t issue)  in response to 
ca f fe ine  as a funct ion of p re-ca f fe ine  whole brain CBF revealed t~e fo l lowing 
re l a t i onsh ip :  Change in CBF = (p re-ca f fe ine  CBF - 29 .4 ) / (1 .21) ;  R ~ = 0.91, 
p < 0.0005. Di f ferences among subjects in plasma caf fe ine leve ls  at ta ined 
did not account fo r  th is  re la t i onsh ip .  
No s i g n i f i c a n t  r i g h t  versus l e f t ,  or an te r io r  versus pos te r io r ,  co r t i ca l  
hemispheric d i f fe rences were observed, e i t he r  before or a f t e r  ca f fe ine  
in fus ion ,  and magnitude of the caf fe ine e f f ec t  did not d i f f e r  s i g n i f i c a n t l y  
among the co r t i ca l  and subcort ical  ROls analyzed. Pat ients had s l i g h t l y  
higher whole-brain CBF leve ls  than normal subjects (12%), which was 
completely due to the higher CBF in the two female pa t ien ts .  Higher CBF in 
women has been reported prev ious ly  (28,29). 
Results fo r  the other dependent var iab les  are presented in Table I .  
Based on a l l  e ight  subjects given intravenous ca f fe ine ,  caf fe ine produced a 
s i g n i f i c a n t  decrease in PaCO 2 (F = 3.67, df = ~,18, p < 0.03),  and a s i g n i f i -  
cant increase in s y s t o l i c  blood pressure (F . I I ,  df = 3,18, p < 0.001). 
Trends were observed fo r  increases in d i a s t o l i c  blood pressure (F = 2.86, 
df = 3,18, p < 0.07) and anx ie ty  level  (F = 2.61, df = 3,18, p < 0.08). The 
small increases in heart rate and plasma catecholamine leve ls  did not reach 
s t a t i s t i c a l  s ign i f i cance .  For these var iab les  normal subjects d i f f e red  from 
pat ients  only fo r  anx ie ty  level  (F = 10.2, df = 1,6, p < 0.02), wi th pat ients 
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higher than normal subjects; no other var iable demonstrated even a trend 
towards a s ign i f i can t  d i f ference.  
Table 1 
Resting Placebo Caffeine 15 Caffeine 45 
Uncorrected Whole Brain CBF 45.9 47.4 32.4 32.4 
[ml/min/lO0 gm of t issue]  (11.9) (9.48) (5.18) (3.02) 
PaCO 2 39.1 39.9 36.6 37.9 
[ t o r r ]  (2.64) (2.41) (3.25) (2.53) 
Plasma Caffeine 0.0 0.0 6.92 5.40 
[mcg/ml] (0.0) (0.0) (2.04) (1.61) 
Plasma Epinephrine 98 126 149 138 
[pg/ml] (86.7) (68.7) (54.4) (45.9) 
Plasma Norepinephrine 230 278 300 265 
[pg/ml] (163) (141) (232) (182) 
Systol ic Blood Pressure 118 120 128 126 
[mm Hg] (9.96) (10.6) (8.35) (12.4) 
Diasto l ic  Blood Pressure 76 76 81 80 
[mm Hg] (5.60) (4.30) (7.16) (8.00) 
Heart Rate 55 57 58 62 
[beats per minute] (11.6) (8.62) (16.0) (10.9) 
Anxiety Level 33 25 38 24 
[O=none, lO0=most] (38.5) (30.4) (39.9) (32.9) 
Mean Levels (and Standard Deviations) for  paCOp-Uncorrected Whole Brain CBF, 
Ar ter ia l  PaCO 2, Ar te r ia l  Plasma Caffeine, E~in~phrine, and Norepinephrine, 
Systol ic and Diasto l ic  Blood Pressures, Heart Rate, and Anxiety Severi ty for 
the Eight Subjects Given Intravenous Caffeine 
For the two subjects given oral caf fe ine,  average decreases for 
PaCO2-corrected CBF were 32%, 36%, and 34% at 15, 45, and 75 minutes fol lowing 
caffeine administrat ion, respect ively (repeated-measures F = 52.0, df = 3,3, 
p < 0.005). Caffeine plasma levels were 4.65, 4.91, and 5.80 mcg/ml, 
respect ively.  Changes in heart rate, blood pressure, and subject ive anxiety 
were also comparable to the other normal subjects. 
Discussion 
Robust decreases in whole-brain CBF were observed fol lowing caffeine 
administrat ion. By using PET methodology, th is is the f i r s t  study which has 
quant i f ied the absolute magnitude of th is  decrease, and has performed regional 
cor t ica l  and subcortical analyses of changes in CBF produced by caffeine. 
These decreases in CBF were produced by commonly consumed amounts of caffeine 
that do not produce impairment of cognit ive performance (18,30); oral and 
intravenous caffeine in the same doses produced CBF decreases of approximately 
equal magnitude. Since mult ip le scans do not produce a consistent change in 
CBF (31), the observed resul ts were not due to repeated scans. Regional 
di f ferences in e f fec t  of caf fe ine on CBF were not apparent; a larger study 
would be needed to ve r i f y  that there are no regional di f ferences in 
sens i t i v i t y  of cerebral blood flow to caf fe ine.  The magnitude of the caf fe ine- 
induced decrease was somewhat dependent on the plasma caffeine level at the 
time of scanning, but was not accounted for  by the decrease in PaC02 ; even 
a f ter  PaCO? correct ion,  66% of the variance in CBF upon repeated scans was 
accounted ~or by the caffeine e f fec t .  The decrease in CBF was strongly 
dependent on the pre-caf fe ine CBF, suggesting that some regulatory mechanism 
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may prevent decreases below some minimum tolerable level (32); th is level 
was approximately 30 ml/min/lO0 gm of t issue in this study. 
Caffeine produced a s ign i f i can t  increase in systo l ic  blood pressure, as 
well as a s ign i f i can t  decrease in p~C02; heart rate and plasma catecholamines 
were non-s ign i f i cant ly  increased. Nowever, none of these ef fects appear to 
account for  the resul ts observed; neither blood pressure increases of the 
magnitude observed in this study (33-35) nor changes of plasma catecholamine 
levels in brain vasculature (36) appear to influence CBF, and, as already 
indicated, resul ts were adjusted for the decrease in PaC02 . Based on pr ior  
research, i t  appears most l i k e l y  that adenosinergic mechanisms mediate the 
e f fec t  of caffeine on CBF. In te res t ing ly ,  although in many circumstances 
CBF and cerebral glucose metabolic rate are closely coupled (37,38), two 
pr ior  studies suggest that caffeine does not a f fect  cerebral glucose 
metabolism (39,40); fur ther  research is needed to determine i f  caffeine 
provides a pharmacological agent which r e l i ab l y  dissociates CBF from cerebral 
glucose metabolism. 
Based on a l l  eight subjects given intravenous caffeine there was a trend 
towards a s ign i f i can t  increase in subjective anxiety ratings in response to 
intravenously administered caffeine, and, as expected, anxiety level (but no 
other dependent var iable) was s i gn i f i can t l y  higher for patients than for 
normal subjects. There was, however, no consistent re lat ionship between CBF 
and subjective anxiety, before or af ter  caffeine administrat ion. The small 
di f ference in CBF between patients and normal subjects appeared to be due 
sole ly to the higher CBF in the female versus the male subjects; a larger 
study is needed to ve r i f y  that the CBF response to caffeine is not d i f fe ren t  
in panic patients than in normal subjects. 
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